Systemic sclerosis & Raynaud's
Thymic stromal lymphopoietin in systemic sclerosis interstitial lung disease: a pilot study
Authors' conclusion
In conclusion, TSLP might have a key role in ILD and skin fibrosis.
Study context
- Population
- Patients with systemic sclerosis (SSc) and healthy controls
- Participants
- 75 vs 20
- Exposure
- SSc patients vs healthy controls
- SScn = 75
- Healthy controls (HC)n = 20reference
- Outcome
- Serum TSLP levels
Methodological detailspilot study, case-control
- Pilot study
- Case-control
Main finding
As reported in the abstract
- Serum thymic stromal lymphopoietin (TSLP) higher in SSc patients than HC
Observational data: associations, not effects.
Further findings
Type 2 inflammation vs No Type 2 inflammation
Serum TSLP in SSc with vs without Type 2 inflammation (subgroup)
P < 0.05
Tomographic fibrosis score (TFS) ≥ 5% vs TFS <5%
Serum TSLP in SSc by TFS (subgroup)
P < 0.001
Correlation of TSLP with mRSS
- Positive correlation, r
- 0.409
- P
- P < 0.001
Correlation of TSLP with FVC
- Negative correlation, r
- −0.356
- P
- P < 0.01
Original publication
Thymic stromal lymphopoietin in systemic sclerosis interstitial lung disease: a pilot study. Clin Exp Rheumatol. Published 11 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →